|
시장보고서
상품코드
2054308
두경부암 치료제 시장 : 약제 클래스별, 판매채널별, 지역별Head and Neck Cancer Drugs Market, By Drug Class, By Sales Channel, and By Geography |
||||||
두경부암 치료제 시장은 2026년에 24억 5,810만 달러로 추계되고 있으며, 2033년까지 40억 7,810만 달러에 이를 것으로 예상되고 있습니다. 2026-2033년 CAGR 7.5%로 성장할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 시장 규모 : 2026년 | 24억 5,810만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간 CAGR : 2026-2033년 | 7.50% | 시장 규모 예측 : 2033년 | 40억 7,810만 달러 |
두경부암이란 코, 목, 부비동, 후두, 그리고 구강 내부 및 그 주변에 발생하는 다양한 악성 종양을 가리키는 의학 용어입니다. 두경부암의 대부분은 편평상피암입니다. 두경부암은 조기에 발견하면 완치율이 높지만, 치료법은 여러 요인에 따라 달라집니다.
시장 역학
두경부암의 부담 증가, 질병 진단에 대한 관심 고조, 흡연 및 음주 증가와 담배 제품 사용률의 높음, 안전하고 효과적인 약물 및 치료법에 대한 높은 수요, 그리고 연구 개발의 활성화가 전 세계 두경부암 치료제 시장의 성장을 가속할 것으로 예상되는 주요 요인입니다.
예를 들어, 2022년 2월, 신시내티 대학교 연구진은 국소 방사선 치료와 면역 요법의 병용 요법이 재발성 두경부암 환자에게 더 효과적인 치료법이 될 수 있는지 검증하기 위한 새로운 임상시험을 시작했습니다.
또한, 2022년 2월, 미국 식품의약국(FDA)은 Kura Oncology, Inc.가 개발한 두경부 편평상피암(HNSCC) 환자용 치료제 ‘티피팔니브’에 대해 획기적 치료법(Breakthrough Therapy)으로 지정했습니다. 이 약물은 효능이 뛰어나고 선택성이 높으며, 경구 투여가 가능합니다.
본 조사의 주요 특징
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장의 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트를 제공합니다.
- 본 조사에서는 기업의 주요 정보, 제품 포트폴리오, 주요 성과, 재무 실적, 전략 등의 지표를 바탕으로 전 세계 두경부암 치료제 시장의 주요 기업 프로파일을 작성하고 있습니다.
- 본 보고서의 인사이트를 바탕으로, 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대해 정보에 입각한 의사결정을 내릴 수 있게 됩니다.
- 본 보고서는 두경부암 치료제 시장에 대한 분석으로, 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 애널리스트 등 해당 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 두경부암 치료제 시장 분석에 활용되는 다양한 전략 매트릭스를 통해 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적 및 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 두경부암 치료제 시장 : 약제 클래스별(2021-2033년)
제5장 세계의 두경부암 치료제 시장 : 판매 채널별(2021-2033년)
제6장 세계의 두경부암 치료제 시장 : 지역별(2021-2033년)
제7장 경쟁 구도
제8장 섹션
AJY 26.06.17Head and Neck Cancer Drugs Market is estimated to be valued at USD 2,458.1 Mn in 2026 and is expected to reach USD 4,078.1 Mn by 2033, growing at a compound annual growth rate (CAGR) of 7.5% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 2,458.1 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.50% | 2033 Value Projection: | USD 4,078.1 Mn |
Head and neck cancer is a medical term used to describe different malignant tumors that develop in or around the nose, throat, sinuses, larynx, and mouth. Most head and neck cancers are squamous cell carcinomas. Head and neck cancer is highly curable if detected early, however, the treatment depends on a number of factors.
Market Dynamics
Growing burden of head and neck cancer, rise in focus on disease diagnosis, increase in cigarette smoking, alcohol consumption, and high use of tobacco, high demand for safe and effective drugs or treatment, and increasing research and development are major factors expected to augment the growth of the global head and neck cancer drugs market.
For instance, in February 2022, University of Cincinnati researchers launched a new clinical trial to examine if the combination of a localized radiation treatment and immunotherapy can be a better treatment for patients with recurrent head and neck cancer.
Moreover, in February 2022, the U.S. FDA granted breakthrough therapy designation to Tipifarnib developed by Kura Oncology, Inc., for the treatment of patients with head and neck squamous cell carcinoma (HNSCC). This is a potent, selective, and orally administered drug.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global head and neck cancer drugs market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Merck & Co., Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Astrazeneca Plc., Fresenius Medical Care AG & CO. KGAA, and F. Hoffmann-la Roche Ltd. (Genentech, Inc.,), among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global head and neck cancer drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global head and neck cancer drugs market.
Market Segmentation
- Global Head and Neck Cancer Drugs Market, By Drug Class (Revenue, USD Mn, 2021 - 2033)
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- Global Head and Neck Cancer Drugs Market, By Sales Channel (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Stores
- Global Head and Neck Cancer Drugs Market, By Geography (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles
- Merck & Co., Inc.
- Eli Lilly and Company
- Bristol-Myers Squibb Company
- Astrazeneca Plc.
- Fresenius Medical Care AG & CO. KGAA
- F.Hoffmann-la Roche Ltd. (Genentech, Inc.)
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Sales Channel
- Market Snapshot, By Geography
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Increasing prevalence of head and neck cancer
- Adverse effects of head and neck cancer drugs
- Increasing demand for safe and effective drugs
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Head and Neck Cancer Drugs Market, By Drug Class, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
- Immunotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
- Targeted Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
5. Global Head and Neck Cancer Drugs Market, By Sales Channel, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
- Drug Stores & Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
- Online Stores
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
6. Global Head and Neck Cancer Drugs Market, By Geography, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Sales Channel, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(USD Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Sales Channel, 2021 - 2033,(USD Mn) Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(USD Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Sales Channel, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Sales Channel, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East and Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Sales Channel, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- South Africa
- North Africa
- Central Africa
7. Competitive Landscape
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Astrazeneca Plc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Fresenius Medical Care AG & CO. KGAA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- F. Hoffmann-la Roche Ltd. (Genentech, Inc.)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Analyst Views
8. Section
- Research Methodology
- About us
